CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer.

S N AleksakhinaM M KramchaninovA D MikushinaS E KubrinaV V PetkauA O IvantsovV M MoiseyenkoE N ImyanitovAglaya G Iyevleva

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)

Presence of CCND1 and/or FGFR1 amplification is associated with worse outcomes of AI therapy in patients with metastatic BC.

Keyphrases

metastatic breast cancer
artificial intelligence
genome wide
copy number
stem cells
machine learning
adipose tissue
skeletal muscle
deep learning
glycemic control
replacement therapy